Literature DB >> 31370738

Re-evaluation of challenging telepathological diagnoses in support of a hospital in Tanzania.

Hans-Ullrich Voelker1, Annette Strehl1, Ansgar Stuefe2, Gerhard Stauch3, Hans-Konrad Mueller-Hermelink4.   

Abstract

Since 2007, a hospital in Tanzania has been supported with histopathological reports via telepathology (TP) by German pathologists. For this, the Internet-based platform iPath is used. The aim of this study was to analyse the rate of discrepancies in defined diagnostic groups. After shipment of paraffin-embedded tissue to Germany, specimens were processed according to recent diagnostic standards. All diagnoses were grouped into eight benign and 11 malignant main categories. The comparison comprised the following categories: 1, identical diagnosis; 2, mild discordance; 3, correct distinction between benign and malignant process, 4, false malignant; 5, false benign; and 6, no primary diagnosis possible. The cohort comprised 396 benign and 336 malignant diseases. Of the benign diseases, 62% were category 1, 23% category 2, 2% category 3, 6% category 4 and 7% category 6. Of the malignant diseases, 42% were category 1, 16% category 2, 12% category 3, 14% category 5 and 15% category 6. Exclusive support with static TP cannot meet all requirements of modern medical diagnostics. However, the project shows a approach for how pathologists in industrial countries can help low-income countries. In difficult cases, the opportunity for a final work-up using additional methods must be given for useful diagnostic purposes.

Keywords:  Telepathology; iPath; low-income country; re-evaluation; telehealth

Year:  2019        PMID: 31370738     DOI: 10.1177/1357633X19866564

Source DB:  PubMed          Journal:  J Telemed Telecare        ISSN: 1357-633X            Impact factor:   6.184


  1 in total

1.  The role of telepathology in diagnosis of pre-malignant and malignant cervical lesions: Implementation at a tertiary hospital in Northern Tanzania.

Authors:  Alex Mremi; Nina Karnøe Bentzer; Bariki Mchome; Joseph Mlay; Jan Blaakær; Vibeke Rasch; Doris Schledermann
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.